drugset
drugset / Trial / NCT00967577

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

NCT00967577 ↗

Phase 1 Completed 20 enrolled Weill Medical College of Cornell University
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate changes in tumor blood flow and disease response to the investigation agent, 177Lu-J591.

Timeline

Start
2009-07
Primary completion
2018-06
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject J591 177LU Monoclonal antibody 70 unknown —

Indications

breast cancer colorectal cancer esophageal cancer glioma head and neck cancer kidney cancer malignant pancreatic neoplasm non-small cell lung carcinoma ovarian cancer